596963 Disclosed are arginine salts of carbidopa and compositions that include for example the arginine salt of carbidopa suitable for continuous administration for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson&rsquos disease, secondary parkinsonism, Huntington&rsquos disease, Parkinson&rsquos-like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, together with administration of levodopa. The pharmaceutically acceptable liquid composition comprises arginine and carbidopa, wherein the composition comprises about 1 % or about 2% to about 6% by weight carbidopa the liquid composition has a pH of about 6.5 to about 9.5 at 25°C and the liquid composition is substantially stable at 25°C for 48 hours or more.
